Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Sohag University | OTHER |
| Alexandria University | OTHER |
Not provided
Not provided
Not provided
Not provided
In this randomized, double-blind, placebo-controlled trial, 116 adults with primary BMS were assigned (1:1) to receive THERAVEX® Total Oral Care Plus or placebo for 8 weeks. Participants rinsed 10 mL for 60 seconds three times daily. The primary outcome was change in burning pain intensity (Numeric Rating Scale, NRS). Secondary outcomes included responder rate (≥2-point NRS reduction), Oral Health Impact Profile-14 (OHIP-14), Xerostomia Inventory, Patient Global Impression of Change (PGIC), and safety assessments.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| THERAVEX® Total Oral Care Plus (Mineral-Ionic Oral Rinse) | Active Comparator |
| |
| Placebo Oral Rinse | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| THERAVEX® Total Oral Care Plus | Device | Participants assigned to the active arm received a mineral-ionic oral rinse containing magnesium chloride and calcium chloride (THERAVEX® Total Oral Care Plus). They were instructed to rinse with 10 mL of the solution for 60 seconds, three times daily, for a total duration of 8 weeks. Participants were advised to refrain from eating or drinking for at least 30 minutes after each use to ensure adequate mucosal exposure. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Burning Pain Intensity (Numeric Rating Scale, NRS) | Change in intraoral burning pain intensity from baseline to Week 8, measured using an 11-point Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain). Participants reported their average daily pain over the preceding week at each assessment time point. | 8 weeks |
Not provided
Not provided
Inclusion Criteria:
Adults aged ≥18 years. Diagnosis of primary Burning Mouth Syndrome (BMS) according to International Classification of Orofacial Pain (ICOP) and ICHD-3 criteria.
Daily intraoral burning or dysaesthetic sensation persisting for ≥3 months and occurring ≥2 hours per day.
Clinically normal oral mucosa without visible lesions. Absence of identifiable local or systemic causes of oral burning following standard diagnostic workup.
Ability and willingness to comply with study procedures and provide written informed consent.
Exclusion Criteria:
Presence of secondary causes of oral burning (e.g., oral candidiasis, nutritional deficiencies, uncontrolled diabetes mellitus, thyroid disorders).
Autoimmune diseases affecting the oral cavity (e.g., Sjögren syndrome). Active oral mucosal pathology or lesions. Pregnancy or breastfeeding. Known hypersensitivity to any component of the study product. Use of topical clonazepam, capsaicin, systemic neuromodulators, or other treatments for BMS within 14 days prior to enrollment.
Severe psychiatric disorders or conditions that could interfere with study participation or outcome assessment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Maxillofacial surgery department, Alexandria university hospital, Alexandria university, Alexandria, Egypt | Alexandria | Egypt |
Yes. Individual Participant Data (IPD) that underlie the results reported in this study, after de-identification, will be made available upon reasonable request to the corresponding author, subject to institutional review and data-sharing agreements.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Quadruple : Participant, Care Provider, Investigator, Outcomes Assessor
|